ETHNIC VARIATIONS IN ANTIDEPRESSANT RESPONSE IN AFRICAN AMERICANS

非裔美国人抗抑郁反应的种族差异

• 批准号: 7609664
• 负责人: HECTOR FRANKLIN MYERS
• 金额: $ 1.94万
• 依托单位: CHARLES R. DREW UNIVERSITY OF MED & SCI
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7609664
• 关键词: African American; Antidepressive Agents; CYP2C19 gene; Celexa; Citalopram; Clinical; Computer Retrieval of Information on Scientific Projects Database; Cytochrome P450; DSM-IV; Enzymes; Funding; Genetic; Genetic Polymorphism; Goals; Grant; Institution; Major Depressive Disorder; Marketing; Mediating; Medical center; Metabolic Biotransformation; Molecular Biology; Neurotransmitters; Pharmacogenetics; Purpose; Research; Research Personnel; Resources; Safety; Selective Serotonin Reuptake Inhibitor; Site; Source; United States National Institutes of Health; Variant; prospective; response; therapeutic target; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this collaborative, multi-site (King-Drew Medical Center, Harbor-UCLA Medical Center and Cedars-Sinai Medical Center) study is to examine the predective value of genetic polymorphism in 200 African American and 200 Caucasina subject who meet DSM-IV criteria for major depression when treated with the antidepressant citolopram (CIT). Recent advances in molecular biology and pharmacogenetics have contributed substantially to the understanding of the genetic control of the pharmacogenetics of the cytochrome P-450 enzymes, as well as the neurotransmitter transporters (therapeutic targets of most antidepressants), tools are now available to enable us to systematically response (kalow, 1992; Lin et al., 1993). In order to pursue these goals, this application proposes to contuct a prospective clinical trail of the safety and efficacy of citalopram (Celexa) (CIT), which is the most selective serotonin reuptake inhibitor (SSRI) that is currently available on the U.S. market (Stahl, 1998). CIT biotransformation is mediated pimarilty by CYP2C19 (Catterson & Preskorn, 1996).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项合作，多站点的目的（国王武器医学中心，苏联医学中心和雪松锡尼医学中心）的研究是检查200名非裔美国人的遗传多态性的预期价值和200名符合DSM-IV符合DSM-IV符合DSM-IV症状的高级抑郁症的预期价值，该标准接受了抗抑郁药的抗抑郁药（Cit）。 分子生物学和药物遗传学的最新进展极大地有助于理解细胞色素P-450酶的药物遗传学的遗传控制，以及神经递质转运蛋白转运蛋白（大多数抗抑郁药的治疗靶标），现在可以使我们对systematically systematically systematically systectationally Respense（kalow），1992； 1992; lin）。 为了实现这些目标，本申请提议构成西妥位丙酰胺（CELEXA）（CIT）的安全性和功效的前瞻性临床轨迹，这是最选择性的5-羟色胺再摄取抑制剂（SSRI），该抑制剂（SSRI）当前在美国市场上可用（Stahl，1998）。 CIP2C19介导了CIT生物转化（Catterson＆Preskorn，1996）。